Compare Heron Therapeutics Inc (HRTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Consumer Staples Select Sector SPDR Fund trades at $84.8. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLP | |
|---|---|---|
Market Cap | $63.41M | — |
Sector | Health | — |
52-Week High | $1.49 | $90.00 |
52-Week Low | $0.32 | $75.61 |
Enterprise Value | $161.31M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
XLP trades at $85.12 with minimal daily movement (+0.01%). The ETF maintains a bullish technical outlook with strong moving average signals and oversold RSI conditions. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights consumer staples sector resilience amid market uncertainty, with Coca-Cola's strong earnings demonstrating the defensive appeal of staple goods companies.
The defensive nature of consumer staples provides stability during market volatility, though limited financial ratio data requires deeper fundamental analysis. Key risks include sector rotation away from defensive plays and macroeconomic pressures on consumer spending. The 2.6% dividend yield offers income appeal for risk-averse investors seeking market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
